[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pericarditis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pericarditis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,70,114,139,166,189,216],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100615100","phase-2-transition-to-kpl-387-monotherapy-dosing--administration-study-100615100",false,"NCT07288216","Transition to KPL-387 Monotherapy Dosing & Administration Study","A Phase 2 Posology Study With Long-Term Extension in Participants With Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy From Standard Therapies","Key Inclusion Criteria:\n\n* Has well-controlled recurrent pericarditis (i.e., including having CRP \\\u003C 0.5 mg\u002FdL within 14 days of Baseline and a pericarditis pain NRS score ≤ 3 at Baseline)\n* Has a documented history of CRP elevation (\\> 1 mg\u002FdL) associated with at least one prior acute pericarditis episode, whether the incident event or any pericarditis recurrence\n* Has received treatment for RP for at least 3 months prior to Baseline with standard therapy(ies) and is currently on a stable dosing regimen including NSAIDs and\u002For colchicine, and\u002For glucocorticoids or an IL-1 pathway inhibitor (anakinra or rilonacept).\n\nKey Exclusion Criteria:\n\n* Has a diagnosis of pericarditis that is secondary to specific prohibited etiologies\n* Has had a pericarditis recurrence in the last 3 months prior to Baseline\n* Has received an investigational drug during the 4 weeks before study drug administration or is planning to receive an investigational drug at any time during the study.\n* Has a history of active or untreated, latent tuberculosis (TB) prior to screening.\n* Has a history of immunodeficiency.\n* Has a history of immunosuppression, including positive human immunodeficiency virus (HIV) test results.\n* Has chest x-ray at Screening or within 12 weeks before first study drug administration, with evidence of malignancy, abnormality consistent with prior or active TB infection or active infection.\n* Has a history of malignancy of any organ system within the past 5 years before Screening (other than a successfully treated non-metastatic cutaneous squamous cell carcinoma or basal cell carcinoma and\u002For localized carcinoma in situ of the cervix).\n* Has a known or suspected current active infection or a history of chronic or recurrent infectious disease (\\> 3 episodes in prior 12 months), including but not limited to, genitourinary infection, chest infection, sinusitis, or skin\u002Fsoft tissue infection.\n* Has had a serious infection, has been admitted to the hospital for an infection, or has been treated for a documented infection requiring antibiotics for a documented infection within 2 weeks prior to first study drug administration.\n* Has had an organ transplant (except corneal transplant performed more than 3 months prior to first study drug administration).\n* In the Investigator's opinion, has any other medical condition that could adversely affect the subject's participation or interfere with study evaluations.","ALL","18 Years","80 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.",[27,28,29],"Recurrent Pericarditis","Heart Diseases","Pericarditis",[31,32,33,27],"Recurrence","Recurrent","KPL-387","RECRUITING","2026-06-18",{"date":37,"type":38},"2026-06-22","ACTUAL",{"date":40,"type":38},"2026-03-25",{"date":42,"type":21},"2029-12-31",{"name":44,"class":45},"Kiniksa Pharmaceuticals International, plc","INDUSTRY",33,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":68,"locationsCount":69},"100593724","phase-2-phase-23-study-of-kpl-387-in-recurrent-pericarditis-100593724","NCT07010159","Phase 2\u002F3 Study of KPL-387 in Recurrent Pericarditis","A Phase 2\u002F3 Efficacy and Safety Study of KPL-387 Treatment in Participants With Recurrent Pericarditis","Key Inclusion Criteria:\n\n* Phase 2 and 3: Has a diagnosis of recurrent pericarditis\n* Phase 2 and 3: Has signs and symptoms of recurrent pericarditis despite treatment with standard therapies\n* Phase 2 and 3: Weighs at least 40 kg\n* Phase 2: Taking NSAIDS and\u002For colchicine (in any combination)\n* Phase 3: Taking NSAIDs and\u002For colchicine and\u002For glucocorticoids (in any combination)\n\nKey Exclusion Criteria:\n\n* Phase 2 and 3: Has a diagnosis of pericarditis that is secondary to specific prohibited etiologies.\n* Phase 2 and 3: Has received an investigational drug during the 4 weeks before screening or is planning to receive an investigational drug at any time during the study.\n* Phase 2 and 3: Has a history of active or untreated, latent tuberculosis (TB) prior to screening.\n* Phase 2 and 3: Has a history of immunodeficiency.\n* Phase 2 and 3: Has a history of immunosuppression, including positive human immunodeficiency virus (HIV) test results.\n* Phase 2 and 3: Has chest x-ray at Screening or within 12 weeks before first study drug administration, with evidence of malignancy, abnormality consistent with prior or active TB infection or active infection.\n* Phase 2 and 3: Has a history of malignancy of any organ system within the past 5 years before Screening (other than a successfully treated non metastatic cutaneous squamous cell carcinoma or basal cell carcinoma and\u002For localized carcinoma in situ of the cervix).\n* Phase 2 and 3: Has a known or suspected current active infection or a history of chronic or recurrent infectious disease (\\> 3 episodes in prior 12 months), including but not limited to, genitourinary infection, chest infection, sinusitis, or skin\u002Fsoft tissue infection.\n* Phase 2 and 3: Has had a serious infection, has been admitted to the hospital for an infection, or has been treated for a documented infection requiring antibiotics for a documented infection within 2 weeks prior to first study drug administration.\n* Phase 2 and 3: Has had an organ transplant (except corneal transplant performed more than 3 months prior to first study drug administration).\n* Phase 2 and 3: In the Investigator's opinion, has any other medical condition that could adversely affect the subject's participation or interfere with study evaluations.",{"count":55,"type":21},165,[24,57],"PHASE3","This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.",[29,60,27],"Pericarditis Acute",[31,32,27,33],"2026-06-04",{"date":64,"type":38},"2026-06-08",{"date":66,"type":38},"2025-07-25",{"date":42,"type":21},{"name":44,"class":45},58,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":94,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":113},"100598885","eacvi-study-on-multimodality-cardiovascular-imaging-of-inflammatory-cardiovascular-diseases-100598885","NCT07077304","EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases","EACVI-INFLAME","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Ability to provide informed non-opposition\n3. Referred for a CMR and\u002For nuclear imaging exam\n\nAND a suspicion of one of the following ICARDs :\n\n1. Suspected Myocarditis (acute or chronic, and whatever the aetiologies)\n2. Suspected Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA)\n3. Suspected Tako-Tsubo\n4. Suspected Pericarditis (acute or chronic, and whatever the aetiologies)\n5. Suspected Connective tissue disease with cardiovascular involvement:\n\n   * Systemic sclerosis\n   * Systemic lupus erythematosus\n   * Antiphospholipid syndrome\n   * Idiopathic inflammatory myopathies\n   * Rheumatoid arthritis, spondylarthritis\n6. Suspected Vasculitis with cardiovascular involvement:\n\n   * Small-vessel vasculitis (ANCA…)\n   * Large vessel vasculitis (Behcet disease, Takayasu…)\n7. Suspected Inflammatory disease with cardiovascular involvement:\n\n   * Sarcoidosis\n   * Still disease\n\nExclusion Criteria:\n\n1. Inability to provide non-opposition\n2. History of heart transplant",{"count":78,"type":21},5000,"OBSERVATIONAL","Inflammatory Cardiovascular Diseases and Autoimmune Rheumatic Diseases (ICARDs) encompass cardiovascular involvement in connective tissue diseases, vasculitis, and primary inflammatory cardiac processes affecting all layers of the heart. ICARDs are associated with increased cardiovascular morbidity and mortality, independently of traditional risk factors, via multiple pathophysiological mechanisms.\n\nDiagnosis and prognosis are challenged by the heterogeneity of clinical presentations. Multimodality cardiovascular imaging - including cardiovascular magnetic resonance (CMR), transthoracic echocardiography, and positron emission tomography (PET) - plays a central role in detecting and characterizing inflammatory involvement, and may offer prognostic insights.\n\nGiven the limited data on the diagnostic and prognostic utility of these imaging modalities in ICARDs, the EACVI-INFLAME study aims to assess the prevalence of confirmed cardiovascular involvement in patients with suspected or established ICARDs undergoing CMR and\u002For cardiac PET in a multicentric international cohort.",[82,83,29,84,85,86,87,88,89,90,91,92,93],"Myocarditis","ANCA Associated Vasculitis","Systemic Sclerosis","Systemic Lupus Erythematosus","Idiopathic Inflammatory Myopathies","Rheumatoid Arthritis","Spondylarthritis","Behcet Disease","Takayasu Arteritis","Sarcoidosis","Still Disease","Tako Tsubo Cardiomyopathy",[95,96,97,98,99,100,101,102],"Cardiovascular disease","Auto-immune disease","Auto-inflammatory disease","Rheumatic disease","CMR","PET","multimodality imaging","ICARD","2026-06-03",{"date":105,"type":38},"2026-06-05",{"date":107,"type":38},"2025-11-19",{"date":109,"type":21},"2028-10-30",{"name":111,"class":112},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":4},"100611843","phase-3-pericardial-imaging-study-100611843","NCT07245849","Pericardial Imaging Study","Identifying Clinical, Serum, and Imaging Based Biomarkers Associated With High-Risk Phenotypes for Recurrent Pericarditis: A Prospective Cohort Study","Inclusion Criteria:\n\n1. History of recurrent pericarditis\\* (i.e. presentation of at lease 2nd episode of acute pericarditis).\n2. Age \\>\u002F= 18 years\n3. Given informed consent\n\n   * standard definitions will be used to define an episode of pericarditis. Pericarditis will be diagnosed by using available published criteria, which includes typical pericardial chest pain, pericardial friction rubs, widespread ST segment elevation or PR-segment depression that was not previously reported and new or worsening pericardial effusion on echocardiography. A clinical diagnosis of acute pericarditis will be made when at least 3 of these criteria are present.\n\nExclusion Criteria:\n\n1. severe valve disease requiring intervention\n2. claustrophobia that precludes FDG\u002FPET or CMR imaging\n3. pregnancy (all women of child bearing potential will have a negative BHCG test)\n4. breastfeeding\n5. glomerular filtration rate (GFR) \\\u003C50 m\u002Fmin\u002F1.72m2",{"count":122,"type":21},44,[57],"The pericardium is a thin, double-layered sac around the heart that helps reduce friction as the heart moves. When this sac gets inflamed, it is called pericarditis, which can cause serious health problems and even be life-threatening. Pericarditis often comes back after the first episode. About 10-30% of people will have it again, and half of those will have it multiple times. Although there are treatments available, they are costly and not often used because we can't predict who best to use them on. Finding a way to predict which patients would benefit from these treatments could help reduce the burden on patients and the healthcare system.\n\nThis study will use a test called an 18F-FDG PET\u002FCT with CTA Scan (18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) with computer tomography angiography (CTA)) to measure inflammation in the pericardium.\n\nThe purpose of the study is to create easy-to-use tools for doctors to identify people at high risk of pericarditis coming back, so they can get advanced treatment early. This study will help fill knowledge gaps about key predictors like clinical signs, blood tests, and imaging results.",[29],[100,127,128],"pericarditis","FDG","NOT_YET_RECRUITING","2026-04-29",{"date":132,"type":38},"2026-05-01",{"date":134,"type":21},"2026-12",{"date":136,"type":21},"2027-07",{"name":138,"class":112},"Ottawa Heart Institute Research Corporation",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":147,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":149,"conditions":150,"keywords":154,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":165},"100628962","cacp-study-on-camptodactyly---arthropathy---coxa-vara---pericarditis-cacp-syndrome-100628962","NCT07468461","CACP: Study on Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome","Profiling Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome: A Multicenter European Study","CACP","Inclusion Criteria:\n\n* Patients with clinical diagnosis and genetic confirmation of CACP syndrome.\n* Patients diagnosed during pediatric age (\\\u003C18 years).\n* Time frame: Patients diagnosed with CACP between January 2005 and January 1, 2026.\n* Informed consent obtained from parents or legal guardians.\n\nExclusion Criteria:\n\n* Patients without genetic confirmation of the diagnosis.\n* Lack of informed consent from parents or legal guardians.\n* Patients diagnosed before January 1, 2005, or after January 1, 2026.",{"count":148,"type":21},15,"CACP syndrome is a rare autosomal recessive disorder characterized by the triad of camptodactyly, non-inflammatory arthropathy with synovial hyperplasia, and coxa vara. Occasionally, non-inflammatory pericarditis and pleural effusion may also occur. This syndrome is likely underdiagnosed due to its rarity. Epidemiological information is limited to isolated case reports or small patient series, with the largest reported cohort including 35 patients.\n\nThe genetic cause of CACP syndrome is associated with mutations in the PRG4 gene, located on chromosome 1q31.1. While clinical signs (camptodactyly, non-inflammatory arthropathy, and coxa vara) and radiological findings suggest the diagnosis, genetic testing confirms it by identifying pathogenic biallelic mutations in PRG4.\n\nTo date, twenty-two mutations have been identified, all leading to premature stop codons and the absence of functional lubricin. However, the exact pathophysiology of CACP syndrome remains incompletely understood.\n\nClinical manifestations of CACP syndrome can vary, even within the same family. The progressive and slow onset can initially present as an incomplete clinical picture. However, camptodactyly (85- 100%) and arthropathy (100%) are constant features.\n\nAlthough genetically homogeneous, CACP exhibits significant intra- and interfamilial phenotypic variability due to secondary genetic factors, environmental modifiers, and complex molecular mechanisms.\n\nCamptodactyly is symmetrical, with variable distribution. It may affect fingers or toes and can be congenital or develop during childhood.\n\nArthropathy is symmetrical, primarily involving large joints (wrists, knees, ankles, elbows, and hips).\n\nCoxa vara is present in 50-90% of cases, is progressive, and tends to worsen with age. Spinal abnormalities such as lordosis, scoliosis, and kyphosis are possible, though the cervical spine is generally spared.\n\nThe articular manifestations of CACP syndrome may mimic juvenile idiopathic arthritis (JIA), and patients are often initially misdiagnosed and treated inappropriately.\n\nJoints appear swollen due to non-inflammatory synovial effusion and synovial thickening. They develop contractures, functional limitations, and sometimes musculoskeletal pain.\n\nNon-inflammatory pericarditis is reported in 30% of published cases, with variable clinical courses that may require surgical intervention in cases of constrictive pericarditis.\n\nThe routine pathway of assessments and follow-up for patients with CACP syndrome includes an initial detailed evaluation and regular monitoring. Following the diagnosis, which is based on clinical history, imaging studies, and genetic confirmation of PRG4 mutations, patients undergo periodic clinical visits, generally scheduled every six months. During these visits, the progression of the disease, articular symptoms (e.g., camptodactyly, mobility limitations), and possible extraarticular complications, such as pericarditis, are assessed.\n\nRadiological (e.g., X-rays, MRI) and laboratory assessments, however, can be spaced out over longer intervals compared to the schedule of clinical visits, typically every 1-2 years, unless specific indications arise. Nonetheless, these examinations may be requested based on contingent clinical needs, such as a sudden worsening of symptoms or suspicion of complications. This flexible approach helps to balance thorough disease monitoring with minimizing the burden on patients, while ensuring personalized and timely management of the condition.\n\nAt present, there is no specific pharmacological treatment for CACP. Management is primarily symptomatic and aimed at preventing joint deformities and extra-articular complications.\n\nCurrently, no experimental therapies are available for CACP syndrome, but future research could explore gene therapy, regenerative medicine, and biologics.\n\nThis study, involving pediatric and pediatric rheumatology centers across Italy and Europe, aims to collect epidemiological, clinical, and therapeutic data from a large cohort of patients. Its goals include better defining the disease's characteristics, understanding its natural history, and evaluating different therapeutic approaches and their efficacy. The study will also analyze potential genotypephenotype correlations.",[151,152,153,29],"Camptodactyly","Arthropathy","Coxa Vara",[155],"Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome","2026-03-13",{"date":158,"type":38},"2026-03-16",{"date":160,"type":38},"2025-08-01",{"date":162,"type":21},"2038-01-01",{"name":164,"class":112},"Meyer Children's Hospital IRCCS",10,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":174,"sex":16,"minAge":175,"maxAge":4,"enrollmentInfo":176,"targetDuration":178,"studyType":79,"phases":4,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":113},"100442793","covid-19-vaccine-induced-inflammatory-heart-disease-prevalence-registry-100442793","NCT05046002","COVID-19 Vaccine-induced Inflammatory Heart Disease Prevalence Registry","COVID-19 Vaccine-induced Inflammatory Heart Disease Prevalence Registry (COVID-VIHPR)","COVID-VIHPR","Inclusion Criteria:\n\n1. All patients eligible for vaccination with a COVID-19 vaccine,\n2. At least one cardiac symptom of suspected myocarditis\u002Fpericarditis within 42 days of receiving a COVID-19 vaccination. The clinical symptoms include chest pain, pressure, or discomfort; dyspnea, shortness of breath\u002Fdyspnea\u002Fpain with breathing, palpitations, diaphoresis, syncope, or sudden death.\n\n   OR At least two non-specific symptoms within 42 days of receiving a COVID-19 vaccination. These symptoms include fatigue, abdominal pain, dizziness or syncope, edema, or cough.\n\n   OR No symptoms, but abnormal histopathology or a combination of abnormal cardiac biomarkers with abnormal cardiac imaging (echo or MRI)\n3. At least one of the following:\n\n   1. Elevations in Troponin T, Troponin I, or CK-MB (above threshold of normal)\n   2. Abnormal MRI (per Brighton Criteria Case Definitions)\n   3. Any new or worsening cardiac arrhythmias on ECG or telemetry or Holter monitor (per Brighton Criteria Case Definitions) including those that normalize on recovery.\n   4. Abnormal Echocardiographic findings (per Brighton Criteria Case Definitions, see Appendix 2 and 3)\n   5. Physical exam finding: Pericardial friction rub or pulsus paradoxus\n   6. Pericardial fluid or inflammation by imaging (echo, MRI, or CT) or at least one of the following elevated biomarkers of inflammation: ESR, CRP, hs-CRP, or D-Dimer.\n   7. Enlarged heart on chest radiograph.\n   8. Histopathologic examination of myocardial tissue (autopsy or endomyocardial biopsy) showed myocardial inflammation\n\nExclusion Criteria:\n\n1. Clear alternative diagnosis or explanation for the symptoms and findings (e.g. infectious myocarditis such as Lyme carditis). Note: Work-up of alternative diagnosis is dependent on clinical presentation e.g. Lyme carditis (e.g. endemic area, season, bullseye rash) or autoimmune heart disease (e.g. arthritis, rash, recurrence).\n2. Symptoms after 42 days of vaccination.",true,"5 Years",{"count":177,"type":21},400,"4 Years","Myocarditis and pericarditis are inflammatory diseases of the myocardium and pericardium, and can be related to different causes, including vaccines. In the past, some people developed inflammatory heart disease after receiving a live or inactive virus vaccine (smallpox vaccine or flu vaccine). Myocarditis was also seen in people with COVID-19. More recently, many countries reported that some people have developed an inflammatory condition of the myocardium or pericardium after receiving a vaccine for COVID-19.\n\nAfter the COVID-19 vaccination campaigns, doctors have noticed more people presenting to the Emergency Department with chest pain and shortness of breath after receiving the vaccine, symptoms that resemble myocarditis or pericarditis. These symptoms may start between 2 to 10 days following vaccination and are frequently noticed after the second dose of the vaccines. While pericarditis seems to affect people of various age groups and gender, myocarditis is more commonly seen in young males.\n\nThe study will consist of two components. 1) The vaccine-induced inflammatory heart disease database will be established. There will be a retrospective chart review looking at vaccine myocarditis\u002Fpericarditis (Brighton Criteria Levels 1-3).\n\n2\\) There will be a prospective, pragmatic design case-control study for vaccine myocarditis\u002Fpericarditis. Follow-up telephone interview will be conducted at 6 months, 12 months and yearly up to 4 years. A record search will also be performed at 6 months, 12 months and yearly for 4 years.\n\nThe retrospective component of the study will be conducted by identifying patients previously diagnosed with this condition at participating centres.",[82,29],"2026-01-26",{"date":183,"type":38},"2026-01-28",{"date":185,"type":38},"2021-08-11",{"date":187,"type":21},"2026-12-31",{"name":138,"class":112},{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":200,"conditions":201,"keywords":202,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":215},"100510388","clinical-phenotypes-in-pericarditis-il-1ra-antibodies-and-supar-levels-100510388","NCT05925790","Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR Levels","Observational Study on Anti-interleukin-1 Receptor Antagonist Antibodies and Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Pericarditis: PERIPLO (PERicarditis: IL-1 RA Antibodies and suPAR Levels Observational) Study","PERIPLO","Inclusion Criteria:\n\n* Written informed consent from patients aged ≥ 18 years before any evaluation is performed.\n* Written informed consent from parents or legal guardian and assent from minors aged under 18 years before any evaluation is performed.\n* Recurrent acute pericarditis during the acute phase of the disease. The diagnosis of pericarditis is based on the presence of at least two of the following criteria: typical pericarditic chest pain (acute and pleuritic, worsened by positional changes or breathing), pericardial friction rub, diffuse ST segment elevation or PR depressions not previously reported, and pericardial effusion.\n* Post-cardiac injury pericarditis (e.g., post-cardiac surgery) that is new or worsening. Recurrence is diagnosed based on the same criteria.\n\nIn all patients, the previous history of CRP values should be known to distinguish individuals with inflammatory forms (characterized by significantly elevated CRP values in the clinical history) from those with pericarditis and normal or near-normal CRP levels (clinical history of normal or at most less than 2 times the normal value).\n\nThe acute phase of the disease is defined as follows: for pericarditis forms with elevated CRP, the presence of a CRP that is at least double the normal value of the test. For forms with normal CRP, it is based on clinical judgment, as there are no other recognized and validated criteria.\n\nExclusion Criteria:\n\n* Specific etiologies, including tuberculosis, neoplastic or purulent etiologies, post-cardiac injury syndromes, and autoimmune rheumatic diseases.\n* Subjects under 18 years of age.\n* Pregnant or lactating women.\n* History of immunosuppression, including a positive result on HIV screening tests (ELISA and Western blot).\n* Positive QuantiFERON test (QFT-Tuberculosis G In-Tube) or positive Purified Protein Derivative (PPD) test after the initial clinical evaluation.\n* History of other significant medical conditions that, according to the investigator, could compromise the outcome or interpretation of the results (e.g., systemic diseases that are not directly the cause of pericarditis but may cause a state of chronic inflammation).\n* Use of any medication that the investigator believes could alter the result of the tests to be performed (except those used for the treatment of pericarditis).\n\nThroughout the study, patients will continue to receive the most appropriate therapies for their clinical condition, following current guidelines and good clinical practice, without the participation in the study prejudicing or influencing the choice of therapeutic strategies to be employed.","90 Years",{"count":199,"type":21},146,"This study aims to investigate the pathophysiology of recurrent pericarditis (RP) by testing for neutralizing autoantibodies against interleukin-1 receptor antagonist (IL-1RA) and measuring soluble urokinase plasminogen activator receptor (suPAR) levels. The hypothesis is that these tests will provide insights into both the inflammatory and non-inflammatory phenotypes of RP, shedding light on the underlying mechanisms. The study will assess the correlation between antibody levels, suPAR levels, and markers of cardiac damage and inflammation. Longitudinal testing during acute episodes and intercritical phases is also planned. The results may guide the use of anakinra, an IL-1 receptor antagonist, in specific clinical scenarios and optimize treatment strategies for RP.",[29],[29,203,204,205],"Anti-interleukin-1 receptor antagonist antibodies","Soluble urokinase plasminogen activator receptor","Pericarditis phenotypes","2024-07-01",{"date":208,"type":38},"2024-07-03",{"date":210,"type":38},"2023-07-01",{"date":212,"type":21},"2025-12-20",{"name":214,"class":112},"ASST Fatebenefratelli Sacco",9,{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":224,"maxAge":4,"enrollmentInfo":225,"targetDuration":227,"studyType":79,"phases":4,"briefSummary":228,"conditions":229,"keywords":234,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":4},"100547697","inflammation-in-acute-cardiovascular-diseases---the-cardiovascular-inflammation-registry-cair-100547697","NCT06411340","Inflammation in Acute Cardiovascular Diseases - the CArdiovascular Inflammation Registry (CAIR)","An Observational-based Registry of Routinely Collected Clinical Parameters to Study Inflammation in Acute Cardiovascular Diseases - the CArdiovascular Inflammation Registry","CAIR","Inclusion Criteria:\n\n* Any patient 13 years of age or older with an acute cardiovascular condition requiring hospital admission is eligible.\n\nExclusion Criteria:\n\n* \\\u003C13 years of age","13 Years",{"count":226,"type":21},1000,"10 Years","Following acute cardiovascular injury, inflammation is vital to activate reparative mechanisms. However, there is compelling evidence implicating excessive inflammation and dysregulated resolution in fibrosis, ventricular remodelling, and heart failure (HF). Recently, the anti-inflammatory agent colchicine reduced cardiovascular events after myocardial infarction (MI) compared to placebo, indicating that targeting inflammation in acute cardiovascular conditions is feasible. Several acute cardiovascular conditions are characterised by inflammation, including myocarditis, MI, and acute heart failure. However, there is large variability in definition, epidemiology, clinical presentation, pathophysiology, and natural history of acute inflammatory cardiovascular diseases. This relates, in part, to the difficulty in performing adequately powered studies. Clinical studies that include sufficient patients and extended observation periods are necessary to address some of these knowledge gaps. This registry aims to collate routinely collected clinical data on patients with acute cardiovascular diseases characterised by inflammation in an observational-based registry. By doing so, the investigators hope to understand the contribution of inflammation to the pathophysiology of acute cardiovascular disease, improve risk stratification, and identify potential novel therapeutic targets.",[230,231,82,29,232,233,28],"Inflammation","Cardiovascular Diseases","Myocardial Infarction","Heart Failure",[230,235,82,236,237,29,238],"Acute cardiovascular disease","Registry","Electronic health records","Myocardial infarction","2024-05-13",{"date":241,"type":38},"2024-05-14",{"date":243,"type":21},"2024-07",{"date":245,"type":21},"2039-07",{"name":247,"class":112},"King's College London"]